The Pharma Data

APRIL 26, 2022

Valneva and Pfizer plan to submit these data for publication and presentation at a future scientific congress. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick. No vaccine-related serious adverse events (SAEs) were observed.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

Drug Target Review

SEPTEMBER 10, 2024

For example, advances in media and feeds have contributed to higher cell protein expression by optimising nutrient availability and reducing accumulation of waste products within a culture. Novel vector design and synthetic promoters have been designed to maximise productivity and enhance gene expression stability.

Drug Development 65

Drug Development Clinical Supply Production Protein Expression 65

The Pharma Data

SEPTEMBER 8, 2020

Overviews of clinical trials and scientific rationale will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 11-13 September 2020. “We

Clinical Trials 52

Clinical Trials Trials Disease FDA Approval 52

The Pharma Data

OCTOBER 28, 2020

Further detail from the first five patients will be presented at the Foundation for Angelman Syndrome Therapeutics (FAST) Global Summit in December 2020. In almost all cases of Angelman syndrome, the maternal UBE3A allele is either missing or mutated, resulting in limited to no protein expression. About Angelman Syndrome.

Protein Expression 40

Protein Expression Therapies Treatment Disease 40

The Anticancer Fund

SEPTEMBER 29, 2021

Please get in touch if you’re interested in discussing research based on the findings presented below ( info@anticancerfund.org ). Data from patients in the clinical trial showed decreased HER2 total protein expression and phosphorylation of AKT and S6 proteins in tumours.

Clinical Trials 40

Clinical Trials Drugs Trials Protein Expression 40

Drug Target Review

MAY 22, 2024

Secondly, circRNAs can be engineered for more efficient protein expression by carefully selecting and optimising the IRES element, a sequence motif derived from viruses and used to initiate cap-independent translation from circRNA. There are three major reasons for why Circio has selected AATD as its lead gene therapy program.

Therapies 59

Therapies RNA Protein Expression DNA 59

The Pharma Data

DECEMBER 3, 2020

Highlights from the Company’s presentations include: BUTTERFLY Observational Study – Baseline Analysis. An initial analysis of data from 17/22 patients who completed one of these assessments showed substantially decreased neurocognitive abilities compared to children of the same age level despite the use of multiple anti-epileptic therapies.

Clinical Trials 52

Clinical Trials Protein Expression Pharmacokinetics Trials 52

The Pharma Data

SEPTEMBER 28, 2021

The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to 6 weeks aged and data supporting the continued clinical investigation of gene therapy, SRP-9001, in Duchenne dystrophy (DMD).

Clinical Trials 52

Clinical Trials Protein Expression Therapies FDA 52

The Pharma Data

APRIL 27, 2022

Based on DESTINY-Breast04 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a significant improvement in both progression-free survival and overall survival Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers.

Therapies 52

Therapies Trials Protein Expression Treatment 52

The Pharma Data

JANUARY 16, 2021

Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform. About JS Bio.

Protein Expression 52

Protein Expression Protein Production Production Drug Development 52

Drug Target Review

MARCH 15, 2024

Transposons preferentially integrate the gene of interest into active transcriptional sites, facilitating rapid cell line development and higher titers of the protein drug. Cell Gene Therapy Insights 2017; 3(2), 131-158, 10.18609/cgti.2017.014. Biotechnol Prog. 2017 Nov;33(6):1468-1475. doi: 10.1002/btpr.2548. Epub 2017 Sep 7.

Engineering 105

Engineering Molecular Biology Protein Expression Medical Schools 105

The Pharma Data

JULY 21, 2021

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi , the bacteria that cause Lyme disease. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

The Pharma Data

AUGUST 9, 2021

We believe this highly sophisticated and specifically engineered ADC is fulfilling its promise to reshape the treatment of HER2-positive metastatic breast cancer, with the goal to move into earlier lines of treatment for HER2-positive breast cancer and many other HER2-expressing tumour types across our broad clinical trial programme.”.

Trials 52

Trials Treatment Clinical Trials Protein Expression 52

The Pharma Data

JANUARY 15, 2021

Results from the DESTINY-Gastric01 trial were presented at the 2020 American Society of Clinical Oncology (ASCO) meeting and published in The New England Journal of Medicine. Enhertu previously received Priority Review and Breakthrough Therapy Designation (BTD) in the U.S. months [95% CI 4.3-6.9] compared to 3.5 months [95% CI 2.0-4.3]

Treatment 52

Treatment Trials Disease Therapies 52

Conversations in Drug Development Trends

MAY 30, 2024

This research community is exploring diverse therapeutic avenues and creative thinking, including gene therapies, cell therapies, immunotherapies, novel drug candidates, and the repurposing of drugs from other indications.

Treatment 81

Treatment Clinical Trials Small Molecule Therapies 81

The Pharma Data

JANUARY 13, 2021

Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. The deal will provide Biogen the rights to use the technology across their portfolio of gene therapy products.

Licensing 52

Licensing Licensing Clinical Trials Vaccine 52

The Pharma Data

OCTOBER 26, 2020

Following the unauthorized download of all abstracts on the SITC website, Transgene is communicating the content of the late-breaking poster abstract that will be presented at the SITC 35th Anniversary Annual Meeting (SITC 2020), to be held virtually November 9-14, 2020. Key findings of the trial: .

Vaccine 40

Vaccine Trials Treatment Virus 40

Conversations in Drug Development Trends

APRIL 7, 2025

Solid tumors present a significant challenge to clinical research due to their complex and heterogeneous nature. This approach improves treatment outcomes over traditional broad-spectrum therapies, which are prone to more side effects and adverse events.

Research 40

Research Clinical Trials Trials Clinical Research 40